Targeting PAX2 for the Induction of DEFB1-MEDIATED Tumor Immunity and Cancer Therapy
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,735,365 | Targeting PAX2 for the Induction of DEFB1-MEDIATED Tumor Immunity and Cancer Therapy In force · Low confidence | Musc Foundation for Research Development | In force | Low confidence | ||
| US 7,964,577 | Targeting PAX2 for the Induction of DEFB1-MEDIATED Tumor Immunity and Cancer Therapy In force · High confidence | Phigenix, Inc. | In force | High confidence | ||
| US 8,623,617 | Detecting PAX2 for the Diagnosis of Breast Cancer In force (reinstated) · Low confidence | Musc Foundation for Research Development | In force (reinstated) | Low confidence | ||
| US 8,722,367 | Detecting PAX2 for the Diagnosis of Breast Cancer In force · Low confidence | Musc Foundation for Research Development | In force | Low confidence | ||
| US 8,431,546 | Targeting PAX2 for the Induction of DEFB1-MEDIATED Tumor Immunity and Cancer Therapy Lapsed Apr 30, 2025 on the fee record Ended Apr 30, 2025 · High confidence | Musc Foundation for Research Development | Lapsed Apr 30, 2025 on the fee record | Ended Apr 30, 2025 | Ended Apr 30, 2025 | High confidence |
| US 8,445,444 | Compositions and Methods for Diagnosing, Treating, and Preventing Prostate Conditions Lapsed May 21, 2025 on the fee record Ended May 21, 2025 · Low confidence | Musc Foundation for Research Development | Lapsed May 21, 2025 on the fee record | Ended May 21, 2025 | Ended May 21, 2025 | Low confidence |
| US 8,461,101 | Targeting PAX2 for the Treatment of Breast Cancer Lapsed Jun 11, 2025 on the fee record Ended Jun 11, 2025 · High confidence | Musc Foundation for Research Development | Lapsed Jun 11, 2025 on the fee record | Ended Jun 11, 2025 | Ended Jun 11, 2025 | High confidence |
| US 8,461,126 | Targeting EN2, PAX2, And/Or DEFB1 for Treatment of Prostate Conditions Lapsed Jun 11, 2025 on the fee record Ended Jun 11, 2025 · High confidence | Musc Foundation for Research Development | Lapsed Jun 11, 2025 on the fee record | Ended Jun 11, 2025 | Ended Jun 11, 2025 | High confidence |
| US 8,633,149 | Targeting PAX2 for the Treatment of Breast Cancer Lapsed Jan 21, 2026 on the fee record Ended Jan 21, 2026 · High confidence | Musc Foundation for Research Development | Lapsed Jan 21, 2026 on the fee record | Ended Jan 21, 2026 | Ended Jan 21, 2026 | High confidence |
| US 8,080,534 | Targeting PAX2 for the Treatment of Breast Cancer Term ended Term ended Oct 16, 2026 · High confidence | Phigenix, Inc. | Term ended | Term ended Oct 16, 2026 | Term ended Oct 16, 2026 | High confidence |
| 16 more patents in this group · Pro | ||||||
10 of 26 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 26, including 11 expired and 4 expiring within the 18 months from Nov 15, 2026.
1 of these is in force and held by Phigenix, Inc..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.